文献速递慢性静脉疾病

使用1470 nm激光的腔内激光消融中长期结局的系统综述与Meta分析

Mid-term and Long-term Outcomes of Endovenous Laser Ablation Utilizing a 1470 nm Laser a Systematic Review and Meta-Analysis.
PubMed 文献 · J Endovasc Ther · 2024-12-16

该系统综述与Meta分析纳入15项研究共2064例患者和2125条主干静脉(1862条大隐静脉),评估1470 nm腔内激光消融的中长期疗效。汇总显示2年、3年、5年主干静脉闭塞率分别为93.51%、89.60%、88.94%,大隐静脉闭塞率分别为93.90%、93.01%、89.06%。Meta回归分析发现线性腔内能量密度(LEED)与大隐静脉闭塞在2年、3年、5年随访均呈统计学显著正相关。

要点

  • 1470 nm腔内激光消融术后2年、3年、5年主干静脉汇总闭塞率分别为93.51%、89.60%、88.94%。
  • 术后2年、3年、5年大隐静脉汇总闭塞率分别为93.90%、93.01%、89.06%。
  • LEED(69至101.7 J/cm)与大隐静脉闭塞在2年、3年、5年随访均呈统计学显著正相关。

核心结论

  • 本综述显示1470 nm设备在主干静脉和大隐静脉的中长期闭塞结局令人满意。
  • 大隐静脉闭塞与LEED之间存在正相关,且在2年、3年和5年随访间期持续存在。
  • 尽管结果良好,仍需进一步研究,不仅关注静脉闭塞等技术方面,也关注静脉曲张复发等关键临床参数,以全面评估EVLA的有效性和持久性。

研究设计与样本

  • 系统检索PubMed、Scopus和Web of Science截至2024年1月发表的文章。
  • 纳入15项研究,包括4项随机对照试验、5项前瞻性研究和6项回顾性病例系列,共2064例患者和2125条主干静脉(其中1862条为大隐静脉)。

主要发现

  • 主干静脉在2年、3年和5年的汇总闭塞率分别为93.51%(95%CI:90.01,95.84)、89.60%(95%CI:82.75,93.93)和88.94%(95%CI:81.59,93.58)。
  • 大隐静脉在2年、3年和5年的汇总闭塞率分别为93.90%(95%CI:90.30,96.21)、93.01%(95%CI:82.80,97.36)和89.06%(95%CI:80.55,94.12)。
  • 深静脉血栓(DVT)和烧伤的汇总发生率分别为1.42%(95%CI:0.87,2.31)和2.64%(95%CI:1.19,5.75)。
  • 总体和永久性神经并发症的汇总发生率分别为4.33%(95%CI:1.62,11.12)和1.70%(95%CI:0.69,4.13)。
  • 随访结束时静脉临床严重程度评分(VCSS)的汇总降低值为平均差(MD)4.96(95%CI:3.87,6.05)。

关键数值与推荐

  • Meta回归分析包括LEED值范围为69至101.7 J/cm,显示LEED与大隐静脉闭塞在2年随访(β=0.0977,p=0.02)、3年随访(β=0.2021,p<0.01)和5年随访(β=0.0534,p=0.01)间期均呈统计学显著正相关。

临床怎么用

  • 本综述结果进一步证实了1470 nm EVLA设备在下肢静脉功能不全治疗中的中长期有效性和安全性,支持其继续使用。
  • LEED与大隐静脉闭塞结局在五年随访间期内持续正相关,突显了LEED在优化长期临床结果中的关键作用,可能为临床医生提供有价值的见解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to investigate the mid-term and long-term efficacy of 1470 nm endovenous laser ablation (EVLA). MATERIAL AND METHODS: We conducted a systematic research on PubMed, Scopus, and Web of science for articles published by January 2024. The primary endpoints were truncal vein and great saphenous vein (GSV) occlusion. RESULTS: Fifteen studies, 4 randomized controlled trials (RCTs), 5 prospective, and 6 retrospective case series, including 2064 patients and 2125 truncal veins (1862 GSV) were included. The pooled truncal vein occlusion estimates at 2, 3, and 5 years were 93.51% (95% confidence interval [CI]: 90.01, 95.84), 89.60% (95% CI: 82.75, 93.93), 88.94% (95% CI: 81.59, 93.58). The pooled GSV occlusion at 2, 3, and 5 years were 93.90% (95% CI: 90.30, 96.21), 93.01% (95% CI: 82.80, 97.36), and 89.06% (95% CI: 80.55, 94.12), respectively. The pooled deep vein thrombosis (DVT) and burn estimates were 1.42% (95% CI: 0.87, 2.31) and 2.64% (95% CI: 1.19, 5.75), respectively. The pooled overall and permanent neurologic complication estimates were 4.33% (95% CI: 1.62, 11.12) and 1.70% (95% CI: 0.69, 4.13), respectively. The pooled Venous Clinical Severity Score (VCSS) reduction by the end of follow-up was, mean difference (MD), 4.96 (95% CI: 3.87, 6.05). Meta-regression analysis including linear endovenous energy density (LEED) values ranging from 69 to 101.7 J/cm elucidated a statistically significant positive association between LEED and GSV occlusion at the 2-year (β=0.0977, p=0.02), 3-year (β=0.2021, p<0.01) and 5-year (β=0.0534, p=0.01) follow-up intervals. CONCLUSION: This review has displayed satisfactory medium and long-term truncal and GSV occlusion outcomes for the 1470 nm device. In addition, a positive association between GSV occlusion and LEED was identified, persisting through the 2-year, 3-year, and 5-year follow-up intervals. Despite these favorable findings further research is imperative, focusing not only on technical aspects, such as vein occlusion but also on critical clinical parameters, including varicose vein recurrence, to comprehensively evaluate the effectiveness and durability of EVLA.Clinical ImpactThis review demonstrated the efficacy and safety of the 1470 nm EVLA device in the treatment of lower limb venous insufficiency over the medium- and long-term periods, further substantiating its continued use. Moreover, the consistent positive association between linear endovenous energy density (LEED) and occlusion outcomes across the five-year follow-up interval highlighted the critical role of LEED in optimizing long-term clinical results, potentially offering valuable insights for practitioners.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bontinis V, Bontinis A, Giannopoulos A, et al. Mid-term and Long-term Outcomes of Endovenous Laser Ablation Utilizing a 1470 nm Laser a Systematic Review and Meta-Analysis. J Endovasc Ther. 2024. PMID: 39676621. doi:10.1177/15266028241305955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。